摘要
目的:研讨连续肾脏替代治疗严重脓毒症的效果及对炎性因子水平的影响。方法:随机从本院2016年5月-2018年7月收治的严重脓毒症患者中抽取80例进行讨论,按随机数字表法分组,其中40例接受血必净治疗(对照组),另40例在血必净治疗基础上再接受连续肾脏替代治疗(研究组)。观察比较两组治疗效果。结果:研究组治疗总有效率(95.00%)高于对照组(62.50%),差异有统计学意义(P<0.05)。两组治疗前各炎性因子比较,差异均无统计学意义(P>0.05)。治疗后,研究组高迁移率族蛋白B1(HMGB1)、肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)均低于对照组(P<0.05)。治疗前,两组CD14^+、CD8^+、CD4^+、淋巴细胞计数比较,差异均无统计学意义(P>0.05)。治疗后,研究组CD14^+、CD4^+、淋巴细胞计数均高于对照组(P<0.05),而两组CD8+比较,差异无统计学意义(P>0.05)。结论:连续肾脏替代治疗严重脓毒症效果突出,且可显著改善其炎性因子水平和免疫指标,值得推广。
Objective:To discuss the effect of continuous renal replacement therapy on severe sepsis and its effect on level of inflammatory factors.Method:80 patients with severe sepsis treated in our hospital from May 2016 to July 2018 were randomly selected for discussion,and they were grouped by random number table method.Among them,40 cases were received Xuebijing treatment(control group),another 40 patients were received continuous renal replacement therapy on the basis of Xuebijing treatment(study group).The treatment effect of the two groups were observed and compared.Result:The total effective rate of the study group(95.00%)was higher than that of the control group(62.50%),the difference was statistically significant(P<0.05).The each inflammatory factors of the two groups before treatment were compared,the differences were not statistically significant(P>0.05).After treatment,the high mobility group protein B1(HMGB1),tumor necrosis factor-α(TNF-α),hypersensitive C reactive protein(hs-CRP)in the study group were lower than those in the control group(P<0.05).CD14^+,CD8^+,CD4^+,lymphocyte counts of the two groups were compared before treatment,the differences were not statistically significant(P>0.05).After treatment,CD14^+,CD4^+and lymphocyte counts in the study group were higher than those in the control group(P<0.05),while there was no significant difference in CD8^+between the two groups(P>0.05).Conclusion:The effect of continuous renal replacement therapy on severe sepsis was prominent.It can significantly improve the level of inflammatory factors and immune indicators,thus it is worth promoting.
作者
章柏平
郭剑
ZHANG Baiping;GUO Jian(The 908th Hospital of Joint Logistic Support Force,Yingtan 335000,China)
出处
《中国医学创新》
CAS
2019年第17期110-113,共4页
Medical Innovation of China
关键词
脓毒症
连续肾脏替代治疗
炎性因子
免疫
Sepsis
Continuous renal replacement therapy
Inflammatory factors
Immunity
